GlassScriptPhysician profile
Kusay Barakat
NPI 1952306730
$10,857.47
in general payments reported to CMS, 2019-2025
45 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,369 · 2020: $1,914 · 2021: $1,662 · 2022: $1,598 · 2023: $1,873 · 2024: $1,246 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,114 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,114.39 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,332.55 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Confirm Rx |
| Sanofi-Aventis U.S. LLC | $1,016.46 | 2019-2024 | |
| Amgen INC. | $668.33 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $658.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $633.23 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $607.72 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $590.20 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $517.03 | 2020-2024 | Nexletol |
| Medtronic, INC. | $500.32 | 2021-2024 | Corevalve Evolut R, Micra, Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $458.81 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $448.68 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $375.25 | 2019-2022 | |
| Pfizer INC. | $322.18 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.66 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $301.81 | 2020-2024 | Watchman, Lux-Dx Insertable Cardiac Monitor |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kusay Barakat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.